It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MKKGY’s FA Score shows that 1 FA rating(s) are green whilePHCUF’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MKKGY’s TA Score shows that 5 TA indicator(s) are bullish while PHCUF’s TA Score has 2 bullish TA indicator(s).
MKKGY (@Pharmaceuticals: Generic) experienced а +4.10% price change this week, while PHCUF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
MKKGY is expected to report earnings on Nov 13, 2025.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
MKKGY | PHCUF | MKKGY / PHCUF | |
Capitalization | 56.5B | 162M | 34,877% |
EBITDA | 6.04B | 44.5M | 13,578% |
Gain YTD | -6.034 | 4.907 | -123% |
P/E Ratio | 17.12 | 772.72 | 2% |
Revenue | 21.3B | 523M | 4,073% |
Total Cash | 1.62B | 239M | 678% |
Total Debt | 8.7B | 0 | - |
MKKGY | PHCUF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 93 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 92 | 100 | |
SMR RATING 1..100 | 70 | 91 | |
PRICE GROWTH RATING 1..100 | 61 | 45 | |
P/E GROWTH RATING 1..100 | 91 | 6 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MKKGY's Valuation (24) in the null industry is significantly better than the same rating for PHCUF (98). This means that MKKGY’s stock grew significantly faster than PHCUF’s over the last 12 months.
MKKGY's Profit vs Risk Rating (92) in the null industry is in the same range as PHCUF (100). This means that MKKGY’s stock grew similarly to PHCUF’s over the last 12 months.
MKKGY's SMR Rating (70) in the null industry is in the same range as PHCUF (91). This means that MKKGY’s stock grew similarly to PHCUF’s over the last 12 months.
PHCUF's Price Growth Rating (45) in the null industry is in the same range as MKKGY (61). This means that PHCUF’s stock grew similarly to MKKGY’s over the last 12 months.
PHCUF's P/E Growth Rating (6) in the null industry is significantly better than the same rating for MKKGY (91). This means that PHCUF’s stock grew significantly faster than MKKGY’s over the last 12 months.
MKKGY | PHCUF | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago22% |
Stochastic ODDS (%) | 3 days ago62% | 3 days ago35% |
Momentum ODDS (%) | 3 days ago61% | 3 days ago24% |
MACD ODDS (%) | 3 days ago64% | 3 days ago35% |
TrendWeek ODDS (%) | 3 days ago60% | 3 days ago30% |
TrendMonth ODDS (%) | 3 days ago56% | 3 days ago26% |
Advances ODDS (%) | 25 days ago61% | N/A |
Declines ODDS (%) | 4 days ago57% | N/A |
BollingerBands ODDS (%) | N/A | 5 days ago13% |
Aroon ODDS (%) | 3 days ago48% | 3 days ago40% |
A.I.dvisor indicates that over the last year, MKKGY has been loosely correlated with MKGAF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MKKGY jumps, then MKGAF could also see price increases.
Ticker / NAME | Correlation To MKKGY | 1D Price Change % | ||
---|---|---|---|---|
MKKGY | 100% | +2.36% | ||
MKGAF - MKKGY | 58% Loosely correlated | +1.94% | ||
LNTH - MKKGY | 27% Poorly correlated | -0.53% | ||
PHCUF - MKKGY | 22% Poorly correlated | N/A | ||
CPHI - MKKGY | 22% Poorly correlated | -2.05% | ||
NPPNY - MKKGY | 11% Poorly correlated | N/A | ||
More |
A.I.dvisor indicates that over the last year, PHCUF has been loosely correlated with HLTRF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PHCUF jumps, then HLTRF could also see price increases.
Ticker / NAME | Correlation To PHCUF | 1D Price Change % | ||
---|---|---|---|---|
PHCUF | 100% | N/A | ||
HLTRF - PHCUF | 38% Loosely correlated | +0.27% | ||
INCR - PHCUF | 26% Poorly correlated | -1.81% | ||
ELAN - PHCUF | 24% Poorly correlated | -0.22% | ||
MKKGY - PHCUF | 22% Poorly correlated | +2.36% | ||
MKGAF - PHCUF | 20% Poorly correlated | +1.94% | ||
More |